• Free Express Shipping on Orders $200+
  • Get Premium-Grade Peptides and Save When You Buy in Bundles
  • Made in the USA

Safety data sheet. GHS / OSHA HCS 2012 format, 16 sections. Issued by Epic Peptides Lab for the catalogue items listed in Section 1.

Epic Peptides Lab

Safety data sheet · lyophilized powder, vial

Epic Peptides Lab · USA

Document number
PL-SDS-074
Revision
1.0 · 2026-10-03

Gonadorelin

lyophilized powder, vial

DANGER

1Identification

Product Identifier
Gonadorelin
Document Number
PL-SDS-074
Catalogue Items Covered
  • Id
    2179
    Name
    Gonadorelin 2mg
    Sku
    PL-GONADORELIN-2MG-VIAL
Recommended Use
Laboratory research use by trained personnel.
Restrictions On Use
Not for human or veterinary use.
Supplier / Distributor
Epic Peptides Lab, USA
Telephone
+1 (787) 468-5291
Email
info@epicpeptideslab.com

2Hazard(s) identification

Classification
  • Reproductive toxicity — Category 2 — H361
  • Specific target organ toxicity, repeated exposure — Category 1 — H372
  • Respiratory sensitisation — Category 1 — H334
  • Skin sensitisation — Category 1 — H317
  • Acute toxicity, inhalation — Category 4 — H332
Label Elements
Pictograms
  • GHS08
  • GHS07
Signal
Danger
Hazard statements
  • H361 Suspected of damaging fertility or the unborn child.
  • H372 Causes damage to organs (reproductive organs) through prolonged or repeated exposure.
  • H334 May cause allergy or asthma symptoms or breathing difficulties if inhaled.
  • H317 May cause an allergic skin reaction.
  • H332 Harmful if inhaled.
Precautionary statements
  • P201 Obtain special instructions before use.
  • P202 Do not handle until all safety precautions have been read and understood.
  • P260 Do not breathe dust, mist or spray.
  • P261 Avoid breathing dust, mist or spray.
  • P264 Wash hands and any exposed skin thoroughly after handling.
  • P270 Do not eat, drink or smoke when using this product.
  • P271 Use only outdoors or in a well-ventilated area.
  • P272 Contaminated work clothing should not be allowed out of the workplace.
  • P280 Wear protective gloves, protective clothing and eye protection.
  • P284 In case of inadequate ventilation wear respiratory protection.
  • P302+P352 IF ON SKIN: Wash with plenty of water.
  • P304+P340 IF INHALED: Remove person to fresh air and keep comfortable for breathing.
  • P308+P313 IF exposed or concerned: Get medical advice/attention.
  • P312 Call a POISON CENTER or doctor if you feel unwell.
  • P314 Get medical advice/attention if you feel unwell.
  • P321 Specific treatment: see Section 4 of this safety data sheet.
  • P333+P313 If skin irritation or rash occurs: Get medical advice/attention.
  • P342+P311 If experiencing respiratory symptoms: Call a POISON CENTER or doctor.
  • P362+P364 Take off contaminated clothing and wash it before reuse.
  • P405 Store locked up.
  • P501 Dispose of contents and container to an approved waste disposal plant in accordance with local, state and federal regulations.
Signal Word
Danger
Other Hazards
No data available.

3Composition / information on ingredients

Description
Lyophilized (freeze-dried) powder or cake in a sealed glass vial with a rubber stopper and aluminium crimp cap.
Composition
  • Name
    Gonadorelin
    Full
    Native gonadotropin-releasing hormone (GnRH, LHRH)
    Cas
    33515-09-2
    Formula
    C55H75N17O13
    Conc
    ≥ 95% (dry basis, as supplied)
    Qty
    2 mg per vial
    Hazards
    • Reproductive toxicity — Category 2 — H361
    • Specific target organ toxicity, repeated exposure — Category 1 — H372
    • Respiratory sensitisation — Category 1 — H334
    • Skin sensitisation — Category 1 — H317
    • Acute toxicity, inhalation — Category 4 — H332

4First-aid measures

First Aid Measures
Inhalation
Move the person to fresh air and keep comfortable for breathing. If breathing is difficult or symptoms persist, call a POISON CENTER or doctor. If experiencing respiratory symptoms (wheezing, shortness of breath), call a POISON CENTER or doctor.
Skin
Take off contaminated clothing and wash it before reuse. Wash the skin with plenty of soap and water. If a rash develops, get medical advice: the material may cause an allergic skin reaction.
Eyes
Rinse cautiously with water for several minutes. Remove contact lenses if present and easy to do; continue rinsing. If eye irritation persists, get medical advice.
Ingestion
Rinse mouth. Do not induce vomiting. Call a POISON CENTER or doctor if you feel unwell.
General
If exposed or concerned, get medical advice. Show this safety data sheet to the doctor. Pregnant or nursing laboratory staff should avoid exposure.
Most Important Symptoms And Effects
allergic skin rash; wheezing, chest tightness or asthma-like symptoms after inhalation in sensitised individuals.
Likely Routes Of Exposure
Inhalation of dust, skin and eye contact when the vial is opened or the powder is weighed; ingestion through contaminated hands; accidental injection when reconstituted solutions are drawn into syringes.

5Fire-fighting measures

Fire Fighting Information
Combustible organic solid; finely divided powder may form dust clouds. Not flammable in the quantities supplied.

6Accidental release measures

Spill And Clean Up Procedures
Avoid dust formation. Dampen spilled powder with water, wipe up with absorbent material, place in a sealed container for disposal and clean the area with water and detergent.

7Handling and storage

Safe Handling
Open vials only in a clean area. Avoid generating or inhaling dust; weigh or reconstitute inside a ventilated enclosure when the full contents are handled as a dry powder. Reconstitute by adding diluent slowly to the vial wall; do not shake. Wash hands after handling.
Safe Storage
Store the sealed vial at the temperature stated in Section 9 (typically −20 °C for peptides, 2–8 °C for proteins), desiccated and protected from light. Allow the vial to reach room temperature before opening to avoid condensation. Reconstituted solutions: 2–8 °C, protected from light; use within the period established by your laboratory.
Storage Temperature
−20 °C (sealed vial), desiccated and protected from light; 2–8 °C acceptable for short periods
Incompatible Materials
Bases and strong acids (PolyPeptide); strong oxidizing agents (generic)

8Exposure controls / personal protection

Occupational Exposure Limits
No data available.
Exposure Controls And PPE
No data available.

9Physical and chemical properties

Physical State
Solid
Appearance
White to off-white lyophilized powder
Properties
Odor
None (PolyPeptide); 'characteristic' (Cayman)
Ph
Not applicable (solid); aqueous solutions typically pH 4–7
Melting
No available data (PolyPeptide); undetermined (Cayman)
Boiling
Not applicable / undetermined
Flash
Not applicable (non-flammable solid); combustible organic material
Vapour
Negligible (solid)
Density
No data available (bulk density of lyophilized cake is low)
Solubility
Soluble in water (PolyPeptide); water 25 mg/mL clear, faintly yellow (ChemicalBook); DMF 30 mg/mL, DMSO 30 mg/mL, PBS 10 mg/mL, ethanol 0.25 mg/mL (Cayman)
Logp
No data available
Decomp
No data available; peptides decompose above about 200 °C
Other
Free peptide C55H75N17O13, MW 1182.3; decapeptide pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2; sold as acetate (CAS 34973-08-5 anhydrous acetate; 71447-49-9 hydrated acetate) or hydrochloride (51952-.

10Stability and reactivity

Stability And Reactivity
Reactivity
Stable under normal conditions; decomposes slowly in aqueous solutions; combustible; dust may form explosive mixture with air (PolyPeptide). No decomposition if used according to specifications (Cayman)
Incompatible
Bases and strong acids (PolyPeptide); strong oxidizing agents (generic)
Decomposition
Carbon and nitrogen oxides (PolyPeptide); Cayman: no dangerous decomposition products known
Conditions To Avoid
Strong heat, light and moisture; avoid generation of dust (PolyPeptide). Store -20 °C (Cayman) or 2-8 °C/-20 °C desiccated
Conditions To Avoid
Strong heat, light and moisture; avoid generation of dust (PolyPeptide). Store -20 °C (Cayman) or 2-8 °C/-20 °C desiccated
Incompatible Materials
No data available.

11Toxicological information

Toxicological Information
  • Acute toxicity, oral

    LD50 oral mouse >4,000 mg/kg; LD50 oral rat >3 g/kg (Cayman); LD50 oral rat >3,000 mg/kg (PolyPeptide)

  • Acute toxicity, dermal

    No data available

  • Acute toxicity, inhalation

    No LD50/LC50; PolyPeptide classifies Acute Tox. 4 inhalation (H332) on a precautionary basis for potent API dust

  • Skin corrosion/irritation

    No irritant effect (Cayman)

  • Serious eye damage/irritation

    No irritating effect (Cayman)

  • Respiratory or skin sensitisation

    Cayman: no sensitizing effects known. PolyPeptide: Skin Sens. 1 and Resp. Sens. 1 (H317, H334) - peptide hormone, allergic reactions (including anaphylaxis) reported clinically

  • Germ cell mutagenicity

    No data available

  • Carcinogenicity

    Not listed by IARC, NTP or OSHA (Cayman, PolyPeptide)

  • Reproductive toxicity

    Cayman: Repr. 2 (H361). ChemicalBook: Repr. 1 (H360). PolyPeptide: 'Gonadotropins may impair fertility and the unborn child. It may cause changes in sex hormones, reduced libido and abortion'; maternal/reproductive effects in rat studies

  • STOT, single exposure

    No data available

  • STOT, repeated exposure

    Cayman: STOT RE 1 (H372). PolyPeptide chronic effects: 'Gonadorelin is also found to cause osteoporosis' (via hypogonadism on chronic exposure)

  • Aspiration hazard

    Not applicable

Routes Of Exposure
Inhalation of dust, skin and eye contact when the vial is opened or the powder is weighed; ingestion through contaminated hands; accidental injection when reconstituted solutions are drawn into syringes.
Symptoms
allergic skin rash; wheezing, chest tightness or asthma-like symptoms after inhalation in sensitised individuals.

12Ecological information

Ecological Information
Cayman: 'Water hazard class 1 (Self-assessment): slightly hazardous for water'. PolyPeptide: no available data on ecotoxicity, persistence, bioaccumulation or mobility. Endocrine-active peptide - avoid release to drains.

13Disposal considerations

Disposal Guidance
No data available.

14Transport information

Transport Classification
Note
Not regulated as a dangerous good for transport by road (DOT 49 CFR), air (IATA/ICAO) or sea (IMDG). Not a marine pollutant. Ship refrigerated or frozen as required by Section 7; the coolant (dry ice, UN 1845) is regulated when used.

15Regulatory information

Regulatory Information
Tsca
Not listed (Cayman: 'Substance is not listed')
Carcinogen Listings
Not listed by IARC, NTP, OSHA, EPA; not on Prop 65
Dea
Not scheduled
Other
WADA: prohibited at all times under S2.2 ('GnRH and its analogues, in males'); PolyPeptide SDS: 'Gonadorelin is on WADA's list of prohibited doping substances (The World Anti-Doping Code): Group S2' - remark only. EU: PolyPeptide notes Directive 92/85/EEC (pregnant/breast-feeding workers) and 'must not be used by persons under 18 years of age'. Approved veterinary drug in the US (Factrel, Cystorelin, Fertagyl; prescription-only) and formerly a human diagnostic.
Carcinogen Listings
No data available.

16Other information

Revision
October 3, 2026
Sources Consulted
  • Cayman Chemical
  • PolyPeptide Group
  • ChemicalBook
Confidence
high
Additional Information
  • Native GnRH decapeptide. Oral LD50 rat > 3,000 mg/kg, mouse > 4,000 mg/kg (Cayman/PolyPeptide).
Back to SDS list
JOIN THE Epic Peptides Lab
Exclusive access for verified researchers only.

Enter your details to access our catalog, COA library,
and research compound database.

By submitting you agree to receive email communications from Epic Peptides Lab You can unsubscribe at any time. All products for in vitro research use only.

  • The Email Catalog
15% off any order

Restock alerts, new compounds and fresh lab results.
We’ll email your code straight away – 15% off, one-time use.

  • ≥99%
  • COA every batch
  • Ships from USA

Research updates only. Unsubscribe any time.